CN102526195B - Medicinal composition for treating coronary disease and preparation method thereof - Google Patents
Medicinal composition for treating coronary disease and preparation method thereof Download PDFInfo
- Publication number
- CN102526195B CN102526195B CN201110247040.2A CN201110247040A CN102526195B CN 102526195 B CN102526195 B CN 102526195B CN 201110247040 A CN201110247040 A CN 201110247040A CN 102526195 B CN102526195 B CN 102526195B
- Authority
- CN
- China
- Prior art keywords
- extract
- moschus
- preparation
- styrax
- eupolyphaga seu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicinal composition for treating coronary disease and a preparation method thereof. The medicinal composition is prepared from musk, bezoar, ginseng extracts, cinnamon, storax, borneol, toad venom, ground beetle and auxiliary materials. The medicinal composition has the effects of activating Yang based on aromatic herbs, inducing resuscitation and relieving pains, and tonifying vital energy and strengthening heart, is used for treating angina pectoris, choking sensation in chest and myocardial infarction caused by myocardial ischemia, and can be used in ischemic myocardium collateral revascularization and medicinal bypass of coronary disease.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of coronary heart disease and preparation method thereof, belong to field of pharmaceutical technology.
Background technology
Angina pectoris, myocardial infarction are a kind of commonly encountered diseases, frequently-occurring disease, are referred to as " mankind the first killer ", serious harm human health, and along with living condition's improvement, the sickness rate of this class disease is more and more higher.How effectively to prevent and treat this worldwide disease is a difficult problem for puzzlement medical circle always.
" Therapeutic Angiogenesis " that medical circle proposes in recent years (being that medicine is put up a bridge) concept has been brought new hope for effectively preventing and treating coronary heart disease.Medicine is put up a bridge and is claimed again Therapeutic Angiogenesis, by some intervention, promote cytokine or the receptor of ischemic myocardium angiogenic growth, promote new little angiogenic growth, foundation is the side Zhi Xunhuan of blood supply effectively, thereby obviously improves ischemic myocardium blood supply, significantly reduces angina pectoris, the generation of the cardiovascular danger events such as myocardial infarction, raising patient's quality of life.In this respect, Chinese medicine has obvious advantage, not only can improve organismic internal environment, regulate, improve human body self-regeneration function, and expense is low, safe, application convenient.Heart pill of Musk is documented in Chinese Pharmacopoeia 2010 editions, by Moschus, Radix Ginseng extract, Calculus Bovis, Cortex Cinnamomi, Styrax, Venenum Bufonis and Borneolum Syntheticum totally 7 herbal medicines be prepared from.There is aromatic herbs activating YANG, the function invigorating vital energy and reinforce the heart, the angina pectoris causing for myocardial ischemia, uncomfortable in chest and myocardial infarction.Heart pill of Musk research and development application is the history of existing more than 30 year so far, is one of common drug of preventing and treating coronary heart disease.Because its curative effect is affirmed, safety economy, and there is unique Role of Therapeutic Angiogenesis, be listed in national essential drugs.But through us, study discovery, the curative effect of Heart pill of Musk is desirable not enough, if develop the medicine that a kind of drug effect is better than Heart pill of Musk, will bring glad tidings for more patients.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of pharmaceutical composition for the treatment of coronary heart disease and preparation method thereof, to solve the dissatisfactory problem of drug effect of Heart pill of Musk.
For solving above technical problem; the present invention is by the following technical solutions: a kind of pharmaceutical composition for the treatment of coronary heart disease; described pharmaceutical composition calculates according to components by weight percent, by Moschus 1-15 part, Calculus Bovis 1-15 part, Radix Ginseng extract 10-50 part, Cortex Cinnamomi 10-50 part, Styrax 5-50 part, Borneolum Syntheticum 1-15 part, Venenum Bufonis 1-15 part, Eupolyphaga Seu Steleophaga 2-20 part and adjuvant, is prepared from.
Concrete; described pharmaceutical composition calculates according to components by weight percent, by Moschus 2-10 part, Calculus Bovis 2-10 part, Radix Ginseng extract 20-40 part, Cortex Cinnamomi 20-40 part, Styrax 10-30 part, Borneolum Syntheticum 2-10 part, Venenum Bufonis 2-10 part, Eupolyphaga Seu Steleophaga 5-15 part and adjuvant, is prepared from.
More specifically, described pharmaceutical composition calculates according to components by weight percent, by 6 parts, Moschus, 6 parts of Calculus Boviss, 30 parts of Radix Ginseng extracts, 30 parts of Cortex Cinnamomis, 20 parts of Styrax, 6 parts of Borneolum Syntheticums, 6 parts of Venenum Bufoniss, 10 parts of Eupolyphaga Seu Steleophagas and adjuvant, is prepared from.
The preparation method of the pharmaceutical composition of described treatment coronary heart disease is: proportionally take Moschus, Calculus Bovis, Radix Ginseng extract, Cortex Cinnamomi, Styrax, Borneolum Syntheticum, Venenum Bufonis and Eupolyphaga Seu Steleophaga; combine with acceptable pharmaceutic adjuvant in medicine; and process according to conventional preparation method, make corresponding pharmaceutical preparation.
Concrete; the pharmaceutical composition of described treatment coronary heart disease is prepared by the following method: Moschus, Calculus Bovis, Radix Ginseng extract, Cortex Cinnamomi, Borneolum Syntheticum, Venenum Bufonis and Eupolyph aga sinesis Walker are broken into fine powder; mix with Styrax and conventional adjuvant, according to conventional method, make pharmaceutical preparation.
Concrete, the pharmaceutical composition of described treatment coronary heart disease is prepared by the following method: Calculus Bovis, Radix Ginseng extract are ground into respectively fine powder; Moschus is pulverized, and doubly measures alcohol reflux 1-3 time of 60-90% with 5-20, each 2-6 hour, and filtration, filtrate recycling ethanol, obtains Moschus extract; Venenum Bufonis is pulverized, and doubly measures alcohol reflux 1-3 time of 60%-95% with 30-100, each 0.5-3 hour, and filtration, filtrate recycling ethanol, obtains Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, and with 5-20, doubly measures water boiling and extraction 1-4 time, and each 0.5-3 hour, filters, concentrated, obtains Eupolyphaga seu steleophaga extract; Cortex Cinnamomi adds 8-10 times of water gaging, with hydrodistillation, extracts volatile oil, obtains Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used respectively dissolve with ethanol; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract, Eupolyphaga seu steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid, Borneolum Syntheticum dissolve with ethanol liquid and conventional adjuvant are mixed, according to conventional method, make pharmaceutical preparation.
Described pharmaceutical preparation refers to any pharmaceutically useful dosage form.Specifically, described pharmaceutical preparation is selected from: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, syrup, drop pill, suck agent, granule, pill, powder, unguentum, sublimed preparation, suspensoid, solution, ejection preparation, freeze-dried powder, high-capacity injection, suppository, ointment, plaster, cream, spray and patch.
Preferably, described pharmaceutical preparation is tablet, capsule, granule, pill and oral liquid.
The preparation method of pill of the present invention is: Moschus, Calculus Bovis, Radix Ginseng extract, Cortex Cinnamomi, Styrax, Borneolum Syntheticum, Venenum Bufonis and Eupolyphaga Seu Steleophaga are total to Six-element and are ground into altogether fine powder, Styrax adds the general ball of proper amount of white spirit, dry, obtains pill.
The preparation method of capsule of the present invention is: Calculus Bovis, Radix Ginseng extract are ground into respectively fine powder; Moschus is pulverized, and doubly measures alcohol reflux 1-3 time of 60-90% with 5-20, each 2-6 hour, and filtration, filtrate recycling ethanol, dry, pulverize, and obtains Moschus extract; Venenum Bufonis is pulverized, and doubly measures alcohol reflux 1-3 time of 60%-95% with 30-100, each 0.5-3 hour, and filtration, filtrate recycling ethanol, dry, pulverize, and obtains Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, and with 5-20, doubly measures water boiling and extraction 1-4 time, and each 0.5-3 hour, filters, concentrated, dry, pulverize, and obtains Eupolyphaga seu steleophaga extract; Cortex Cinnamomi adds 8-10 times of water gaging, with hydrodistillation, extracts volatile oil, obtains Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used respectively dissolve with ethanol; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract, Eupolyphaga seu steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid and Borneolum Syntheticum dissolve with ethanol liquid are mixed; add the dextrin of 10-30%, the starch of 5-10%; by equivalent multiplication method mix homogeneously; the HPMC solution soft material processed that adds 2-4%; granulate, dry, granulate; be sub-packed in capsule shells, obtain capsule.
The preparation method of tablet of the present invention is: Calculus Bovis, Radix Ginseng extract are ground into respectively fine powder; Moschus is pulverized, and doubly measures alcohol reflux 1-3 time of 60-90% with 5-20, each 2-6 hour, and filtration, filtrate recycling ethanol, dry, pulverize, and obtains Moschus extract; Venenum Bufonis is pulverized, and doubly measures alcohol reflux 1-3 time of 60%-95% with 30-100, each 0.5-3 hour, and filtration, filtrate recycling ethanol, dry, pulverize, and obtains Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, and with 5-20, doubly measures water boiling and extraction 1-4 time, and each 0.5-3 hour, filters, concentrated, dry, pulverize, and obtains Eupolyphaga seu steleophaga extract; Cortex Cinnamomi adds 8-10 times of water gaging, with hydrodistillation, extracts volatile oil, obtains Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used respectively dissolve with ethanol; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract, Eupolyphaga seu steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid and Borneolum Syntheticum dissolve with ethanol liquid are mixed; add the dextrin of 20%-40%, the magnesium stearate of 0.2%-0.7% mixes; granulate, tabletting, obtains tablet.
The preparation method of granule of the present invention is: Calculus Bovis, Radix Ginseng extract are ground into respectively fine powder; Moschus is pulverized, and doubly measures alcohol reflux 1-3 time of 60-90% with 5-20, each 2-6 hour, and filtration, filtrate recycling ethanol, obtains Moschus extract; Venenum Bufonis is pulverized, and doubly measures alcohol reflux 1-3 time of 60%-95% with 30-100, each 0.5-3 hour, and filtration, filtrate recycling ethanol, obtains Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, and with 5-20, doubly measures water boiling and extraction 1-4 time, and each 0.5-3 hour, filters, concentrated, obtains Eupolyphaga seu steleophaga extract; Cortex Cinnamomi adds 8-10 times of water gaging, with hydrodistillation, extracts volatile oil, obtains Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used respectively dissolve with ethanol; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract, Eupolyphaga seu steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid and Borneolum Syntheticum dissolve with ethanol liquid are mixed; add the Icing Sugar of 20-50% to mix; granulation, dry, obtain granule.
The preparation method of oral liquid of the present invention is: Calculus Bovis, Radix Ginseng extract are ground into respectively fine powder; Moschus is pulverized, and doubly measures alcohol reflux 1-3 time of 60-90% with 5-20, each 2-6 hour, and filtration, filtrate recycling ethanol, obtains Moschus extract; Venenum Bufonis is pulverized, and doubly measures alcohol reflux 1-3 time of 60%-95% with 30-100, each 0.5-3 hour, and filtration, filtrate recycling ethanol, obtains Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, and with 5-20, doubly measures water boiling and extraction 1-4 time, and each 0.5-3 hour, filters, concentrated, obtains Eupolyphaga seu steleophaga extract; Cortex Cinnamomi adds 8-10 times of water gaging, with hydrodistillation, extracts volatile oil, obtains Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used respectively dissolve with ethanol; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract, Eupolyphaga seu steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid and Borneolum Syntheticum dissolve with ethanol liquid are mixed, be dissolved in water, cold preservation 50-100 hour, filters; Separately getting sucrose adds in the water boiling and makes to be uniformly dissolved, filter, make simple syrup, simple syrup is added and in said medicine filtrate, makes final sugar content 10-40%, add 0.1%-0.3% sodium benzoate, boil dissolving, add water to full dose, with sodium hydroxide, adjust PH to 5-6, stir evenly, filter, embedding, obtains oral liquid.
Pharmaceutical preparation of the present invention is determined usage and dosage according to patient's situation in use.
Pharmaceutical composition of the present invention is when making medicament, and the medicament of unit dose can contain pharmaceutically active substance 0.1-1000mg of the present invention, and all the other are pharmaceutically acceptable adjuvant.Pharmaceutically acceptable adjuvant can be the 0.1-99.9% of total formulation weight amount by weight.
Pharmaceutical composition of the present invention is on the basis of Heart pill of Musk prescription, increases Eupolyphaga Seu Steleophaga prescription and obtains.Show that after deliberation Eupolyphaga Seu Steleophaga is the strongest to the improvement effect of each parameter of hemorheological property: length, weight in wet base, the dry weight that can reduce external thrombus, shorten thrombelastogram, maximum setting time, reduce platelet aggregation number, improve Platelet, reduce platelet adhesion reaction, improve erythrocyte deformability, speed erythrocyte electrophoresis speed, improve erythrocyte aggregation, and can reduce fibrinogen content in blood plasma.The present invention increases Eupolyphaga Seu Steleophaga on the basis of Heart pill of Musk prescription, can strengthen the blood coagulation resisting function in medicine, for the stickiness that improves blood, has more obvious effect.But Eupolyphaga Seu Steleophaga is slightly poisonous, can make heart sinus rate slow down, in addition in Eupolyphaga Seu Steleophaga contained alkaloid to the toxicity of heart, the increase with dosage increases.If the prescription consumption of Eupolyphaga Seu Steleophaga is too small, do not reach the object that increases drug effect, if prescription consumption is excessive, can increase the toxicity to heart again, so the amount of how to confirm Eupolyphaga Seu Steleophaga in prescription, be difficult point of the present invention.
In pharmaceutical composition of the present invention, Moschus blood circulation promoting and blood stasis dispelling, the pain relieving of having one's ideas straightened out, is monarch drug.Ginseng qi-tonifying spleen invigorating; Cortex Cinnamomi warming YANG and promoting blood circulation, the Venenum Bufonis pain relieving of having one's ideas straightened out, Styrax aromatic herbs activating YANG, is ministerial drug altogether; Artificial Calculus Bovis's refreshment of having one's ideas straightened out, Eupolyphaga Seu Steleophaga removing blood stasis with potent drugs blood, the Borneolum Syntheticum pain relieving of having one's ideas straightened out, is adjuvant drug altogether.All medicines share, and play altogether aromatic herbs activating YANG, the pain relieving of having one's ideas straightened out, the merit invigorating vital energy and reinforce the heart.The angina pectoris, uncomfortable in chest, the myocardial infarction that for myocardial ischemia, cause, also can be used for the regeneration of coronary heart disease ischemic myocardium collateral blood vessels and medicine and put up a bridge.Applicant has carried out pharmacodynamics and anxious poison experiment to pharmaceutical preparation, and experimental result is as follows:
Experimental example 1: pharmacodynamic experiment research
1 materials and methods
1.1 experiment material
1.1.1 laboratory animal
100 of male SD rats, body weight (320 ± 20) g, is provided by Shanghai Medical Univ's Experimental Animal Center.
1.1.2 experimental apparatus and medicine
Respirator model: Medical Instrument Factory affiliated to Zhejiang Univ manufacture; IMS cell image analytical system: Shanghai Shen Teng information technology companies produces; Pentobarbital sodium: Solution on Chemical Reagents in Shanghai company of Chinese Medicine group; Gentamicin injection liquid: Shanghai No.1 Bio-Chemical Pharmacetical Industry Co., Ltd; Factor rabbit source property polyclonal antibody: Denmark DAKO company; Bfgf-ESSEX: Yisheng Biological Pharmaceutical Co., Ltd., Shuhai; Heparin sodium injection: Jiangsu Province, China Changzhou biochemical Qian Hong pharmaceutical Co. Ltd; Heart pill of Musk: Shanghai and xanthate industry; Pill of the present invention: according to method preparation described in the embodiment of the present invention 1.
The foundation of 1.2 animal models
1.2.1 animal model
Ketalar for rat (80mg/kg) intraperitoneal anesthesia, connects artificial respirator assisted respiartion after tracheotomy.At left breast 4-5 rib catch cropping transverse incision, from blunt separation between the 4th rib of left side, open thoracic cavity, push gently thoracic cavity, expose heart, cut off pericardium, at pulmonary conus and left auricle boundary, slightly descend non-invasive suture ligature left side coronary artery, then layer-by-layer suture thoracic wall for 1-2mm place, open instant recording lead electrocardiogram behind front, with the following cardiac muscle in ligation position bleach beat weaken and electrocardiogram occur the ST section back of a bow upwards obviously raise into modeling successfully.Modeling began the same day ip gentamycin pin 1 time every day (20,000 u/kg body weight), altogether 3d.
1.2.2 grouping and administration
Rat is divided into 6 groups: pill group of the present invention (1 group), Heart pill of Musk group (2 groups), multiple Ji and 3 groups of heparin coupling matched groups (}), model group (4 groups), Sham-operated control group (5 groups) and Normal group (6 groups), every group 8-12, administration as follows respectively.1 group begins to give pill 25mg/kg of the present invention after heart infarction modeling every day, and (adding normal saline to make 2mL suspension) ig continues 8 weeks; 2 groups begin to give Heart pill of Musk 25mg/kg (adding normal saline to make 2mL suspension) ig after heart infarction modeling every day, continue 8 weeks; 3 groups are given bFGF sprinkling 1 around in ligation place immediately and lift (125AU), postoperative sc heparin 1 time every day beginning (1250u/kg), altogether Sd after opening breast knot to prick arteria coronaria; 4 groups of normal saline 2mLig every day that begin after heart infarction modeling, totally 8 weeks.5 groups of not ligation arteria coronaria after opening breast, sew up thoracic wall and only wear 1 time at corresponding site with atraumatic suture needle sky.Normally raise for 6 groups, without any intervention.After 8 weeks, put to death animal, stay heart preparation, 10% formalin is fixed.
1.2.3 infarct size detects
Heart after fixing is through routine dehydration, transparent, paraffin embedding, section, haematoxylin-Yihong (H-E) dyeing, light Microscopic observation myocardial necrosis situation.By IMS cytological image analyses system, under 10 times of object lens microscopes, test, detect respectively myocardial infarction area and left chamber area, myocardial infarction area for infarct size (%)/left chamber area x100% represents.
1.2.4 blocking marginal zone myocardial vascular surface density detects
Section after cardiac muscular tissue's factor immunohistochemical staining, through IMS cytological image analyses system, process, measure the number of blood vessel that infraction marginal zone, left chamber shows factor positive staining, every section 5 visuals field of random observation (x100), get mean, then according to measurement window area, can to calculate the number of blood vessel of every square millimeter be surface density.
1.3 detect index
Infarct size, blood vessel surface density.
2 results
2.1 modelings and animal dead situation
Experiment shares removes 100 male SD rats.Get wherein 82 rats and cause heart infarction model, interior dead 34 of operation 24h, 48 of survival are divided into pill group of the present invention, Heart pill of Musk group, positive drug matched group (Bfgf-ESSEX adds heparin) and negative medicine matched group, every group each 12.8 of normal group and 10 rats of sham operated rats are all not dead.In feeding process, each dead 1 of low dose of, heavy dose of Heart pill of Musk positive controls and model group.
2.2 infarct size comparisons
Under mirror, find that sham operated rats and Normal group also have few part myocardial necrosis.Cervical vertebra dislocation method is put to death rat and is opened behind thoracic cavity, all rat hearts are all being beated, therefore the myocardial infarction of considering sham operated rats and normal rats small size may can cause part myocardial necrosis relevant with the anaerobic condition of rat cadavers after execution rat, the infarction of this fraction is striped muscle fracture, and the infarction of 4 heart infarction rat groups all has fibrosis.
Each organizes testing result with mean standard deviation (x ± s) expression, uses relatively each group difference of multiple comparisons variance analysis, adopts SPSS10.0 software to add up.The results are shown in Table 1
The impact of table 1 on rat myocardial infarction model area
As can be seen from Table 1, the infarct size of model group is maximum, has the difference of highly significant with the infarct size of sham operated rats and normal group, and P<0.01, illustrates that heart infarction modeling is successful.Although sham operated rats is slightly larger than the infarct size of normal group, difference does not have significance, and P > 0.05 illustrates out that breast itself is little on infarct size impact.1 group, 2 groups of medication and 3 groups with model group than all significantly reducing infarct size.Heart pill of Musk group infarct size does not have remarkable statistical significance with positive controls than difference, and P>0.05 illustrates that the effect of Heart pill of Musk reduction infarct size and positive control medicine is similar; The infarct size of pill group of the present invention and positive controls ratio, difference has significance, P<0.05, with the comparison of Heart pill of Musk group, difference also has significance, P<0.05, illustrates that pill group of the present invention is better than Bfgf-ESSEX in effect aspect minimizing infarct size and adds heparin group and Heart pill of Musk group.
2.3 infarction marginal zone blood vessel surface density comparisons
Each organizes testing result with mean standard deviation (x ± s) expression, uses relatively each group difference of multiple comparisons variance analysis, adopts SPSS10.0 software to add up, and the results are shown in Table 2.
The impact of table 2 on rat myocardial infarction model marginal zone blood vessel surface density
As can be seen from Table 2, the blood vessel surface density of model group is higher than sham operated rats and normal group, and difference has statistical significance, P<0.05.The angiogenesis that compensatory occurs after heart infarction is described.And sham operated rats with normal group than no significant difference, P > 0.05, illustrates that operation itself is little on result impact.1 group, 2 groups and 3 groups of medication all have remarkable angiogenesis effect, P<0.01 with model group ratio.Pill group of the present invention is compared with positive control medicine group, the difference not statistically signigicant of blood vessel surface density, P>0.05; Pill group of the present invention is compared with the blood vessel surface density of Heart pill of Musk group, P<0.05, and significant difference, illustrates that pill group of the present invention is in group.
3 discuss
Known according to experimental result, medicine of the present invention is being better than Heart pill of Musk aspect minimizing rat myocardial infarction model area and angiogenesis promoting effect.
Experimental example 2: acute toxicity testing research
1, according to each medicament composing prescription in table 3, according to the method for the invention, be prepared into pill.
Table 3
2, give said medicine to the disposable gavage of mice, observe 14 days, survey its LD
50, the results are shown in Table 4:
Table 4
Known according to above-mentioned experimental result, along with the increasing of Eupolyphaga Seu Steleophaga dosage, drug toxicity increases, and considers the medicinal effects of medicine, and selecting the prescription of medicine 4 is best prescription.
Beneficial effect of the present invention: compared with prior art, medicine of the present invention can have aromatic herbs activating YANG, the pain relieving of having one's ideas straightened out, the effect invigorating vital energy and reinforce the heart, the angina pectoris, the uncomfortable in chest and myocardial infarction that for myocardial ischemia, cause, also can be used for the regeneration of coronary heart disease ischemic myocardium collateral blood vessels and medicine and put up a bridge.Medicine of the present invention and Heart pill of Musk comparison, drug effect obviously increases, and has reached goal of the invention.
The specific embodiment:
Embodiment 1
Prescription: Moschus 6g, Calculus Bovis 6g, Radix Ginseng extract 30g, Cortex Cinnamomi 30g, Styrax 20g, Borneolum Syntheticum 6g, Venenum Bufonis 6g, Eupolyphaga Seu Steleophaga 10g
Preparation technology is: Moschus, Calculus Bovis, Radix Ginseng extract, Cortex Cinnamomi, Styrax, Borneolum Syntheticum, Venenum Bufonis and Eupolyphaga Seu Steleophaga are total to Six-element and are ground into altogether fine powder, Styrax adds the general ball of proper amount of white spirit, dry, obtains pill.
Usage and dosage: oral, 1～2 ball, 3 times on the one; Or take during paresthesia epilepsy.
Embodiment 2
Prescription: Moschus 15g, Calculus Bovis 15g, Radix Ginseng extract 50g, Cortex Cinnamomi 50g, Styrax 50g, Borneolum Syntheticum 15g, Venenum Bufonis 15g, Eupolyphaga Seu Steleophaga 20g
Preparation technology is: Calculus Bovis, Radix Ginseng extract are ground into respectively fine powder; Moschus is pulverized, with the alcohol reflux of 5 times of amounts 60% 3 times, and each 2 hours, filtration, filtrate recycling ethanol, dry, pulverize, and obtains Moschus extract; Venenum Bufonis is pulverized, with the alcohol reflux of 30 times of amounts 60% 3 times, and each 0.5 hour, filtration, filtrate recycling ethanol, dry, pulverize, and obtains Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, by 5 times of amount water boiling and extraction 4 times, and each 0.5 hour, filter, concentrate, dry, pulverize, obtain Eupolyphaga seu steleophaga extract; Cortex Cinnamomi adds 8 times of water gagings, with hydrodistillation, extracts 1 hour, obtains Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used respectively dissolve with ethanol; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract, Eupolyphaga seu steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid and Borneolum Syntheticum dissolve with ethanol liquid are mixed; add 20% dextrin, 5% starch; by equivalent multiplication method mix homogeneously; add 3% HPMC solution soft material processed; granulate, dry, granulate; be sub-packed in capsule shells, obtain capsule.
Usage and dosage: oral, one time 3,3 times on the one; Or take during paresthesia epilepsy.
Embodiment 3
Prescription: Moschus 1g, Calculus Bovis 1g, Radix Ginseng extract 10g, Cortex Cinnamomi 10g, Styrax 5g, Borneolum Syntheticum 1g, Venenum Bufonis 1g, Eupolyphaga Seu Steleophaga 2g
Preparation technology is: Calculus Bovis, Radix Ginseng extract are ground into respectively fine powder; Moschus is pulverized, with the alcohol reflux of 10 times of amounts 85% 2 times, and each 3 hours, filtration, filtrate recycling ethanol, obtains Moschus extract; Venenum Bufonis is pulverized, and with the alcohol reflux of 100 times of amounts 95% 3 hours, filtration, filtrate recycling ethanol, obtains Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, by 10 times of amount water boiling and extraction 4 times, and each 2 hours, filter, concentrate, obtain Eupolyphaga seu steleophaga extract; Cortex Cinnamomi adds 9 times of water gagings, with hydrodistillation, extracts 0.5 hour, obtains Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used respectively dissolve with ethanol; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract, Eupolyphaga seu steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid and Borneolum Syntheticum dissolve with ethanol liquid are mixed, add 40% Icing Sugar to mix, granulation, dry, obtain granule.
Usage and dosage: oral, a 5g, 3 times on the one; Or take during paresthesia epilepsy.
Embodiment 4
Prescription: Moschus 15g, Calculus Bovis 1g, Radix Ginseng extract 10g, Cortex Cinnamomi 50g, Styrax 50g, Borneolum Syntheticum 1g, Venenum Bufonis 1g, Eupolyphaga Seu Steleophaga 20g
Preparation technology is: Calculus Bovis, Radix Ginseng extract are ground into respectively fine powder; Moschus is pulverized, with the alcohol reflux of 15 times of amounts 70% 13 times, and each 16 hours, filtration, filtrate recycling ethanol, obtains Moschus extract; Venenum Bufonis is pulverized, with the alcohol reflux of 30 times of amounts 60% 3 times, and each 1 hour, filtration, filtrate recycling ethanol, obtains Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, by 15 times of amount water boiling and extraction 3 times, and each 1 hour, filter, concentrate, obtain Eupolyphaga seu steleophaga extract; Cortex Cinnamomi adds 10 times of water gagings, with hydrodistillation, extracts volatile oil, obtains Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used respectively dissolve with ethanol; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract, Eupolyphaga seu steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid and Borneolum Syntheticum dissolve with ethanol liquid are mixed, be dissolved in water, cold preservation 72 hours, filters; Separately get sucrose and add in the water boiling and make to be uniformly dissolved, filter, make simple syrup, simple syrup is added and in said medicine filtrate, makes final sugar content 20%, add 0.2% sodium benzoate, boil dissolving, add water to 100ml, with sodium hydroxide, adjust PH to 5-6, stir evenly, filter, embedding, obtains oral liquid.
Usage and dosage: oral, a 5ml, 3 times on the one; Or take during paresthesia epilepsy.
Embodiment 5
Prescription: Moschus 10g, Calculus Bovis 10g, Radix Ginseng extract 40g, Cortex Cinnamomi 40g, Styrax 30g, Borneolum Syntheticum 10g, Venenum Bufonis 10g, Eupolyphaga Seu Steleophaga 15g
Preparation technology is: Moschus, Calculus Bovis, Radix Ginseng extract, Cortex Cinnamomi, Styrax, Borneolum Syntheticum, Venenum Bufonis and Eupolyphaga Seu Steleophaga are total to Six-element and are ground into altogether fine powder, Styrax adds the general ball of proper amount of white spirit, dry, obtains pill.
Usage and dosage: oral, 1～2 ball, 3 times on the one; Or take during paresthesia epilepsy.
Embodiment 6
Prescription: Moschus 2g, Calculus Bovis 2g, Radix Ginseng extract 20g, Cortex Cinnamomi 20g, Styrax 10g, Borneolum Syntheticum 2g, Venenum Bufonis 2g, Eupolyphaga Seu Steleophaga 5g
Preparation technology is: Calculus Bovis, Radix Ginseng extract are ground into respectively fine powder; Moschus is pulverized, with the alcohol reflux of 8 times of amounts 80% 3 times, and each 5 hours, filtration, filtrate recycling ethanol, obtains Moschus extract; Venenum Bufonis is pulverized, with the alcohol reflux of 70 times of amounts 70% 2 times, and each 2 hours, filtration, filtrate recycling ethanol, obtains Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, by 12 times of amount water boiling and extraction 2 times, and each 1 hour, filter, concentrate, obtain Eupolyphaga seu steleophaga extract; Cortex Cinnamomi adds 10 times of water gagings, with hydrodistillation, extracts volatile oil, obtains Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used respectively dissolve with ethanol; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract, Eupolyphaga seu steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid and Borneolum Syntheticum dissolve with ethanol liquid are mixed, be dissolved in water, cold preservation 50 hours, filters; Separately get sucrose and add in the water boiling and make to be uniformly dissolved, filter, make simple syrup, simple syrup is added and in said medicine filtrate, makes final sugar content 10%, add 0.1% sodium benzoate, boil dissolving, add water to 100ml, with sodium hydroxide, adjust PH to 5-6, stir evenly, filter, embedding, obtains oral liquid.
Usage and dosage: oral, a 5-10ml, 3 times on the one; Or take during paresthesia epilepsy.
Embodiment 7
Prescription: Moschus 2g, Calculus Bovis 10g, Radix Ginseng extract 40g, Cortex Cinnamomi 20g, Styrax 10g, Borneolum Syntheticum 10g, Venenum Bufonis 10g, Eupolyphaga Seu Steleophaga 5g
Preparation technology is: Calculus Bovis, Radix Ginseng extract are ground into respectively fine powder; Moschus is pulverized, with the alcohol reflux of 20 times of amounts 90% 3 times, and each 2 hours, filtration, filtrate recycling ethanol, dry, pulverize, and obtains Moschus extract; Venenum Bufonis is pulverized, and with the alcohol reflux of 100 times of amounts 95% 3 hours, filtration, filtrate recycling ethanol, dry, pulverize, and obtains Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, and by 20 times of amount water boiling and extraction 3 hours, filters, and concentrates, and dry, pulverize, and obtains Eupolyphaga seu steleophaga extract; Cortex Cinnamomi adds 10 times of water gagings, with hydrodistillation, extracts 3 hours, obtains Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used respectively dissolve with ethanol; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract, Eupolyphaga seu steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid and Borneolum Syntheticum dissolve with ethanol liquid are mixed; add 30% dextrin, 0.5% magnesium stearate to mix; granulate, tabletting, obtains tablet.
Usage and dosage: oral, one time 3,3 times on the one; Or take during paresthesia epilepsy.
Claims (2)
1. a pharmaceutical composition for the treatment of coronary heart disease; described pharmaceutical composition calculates according to components by weight percent, by 6 parts, Moschus, 6 parts of Calculus Boviss, 30 parts of Radix Ginseng extracts, 30 parts of Cortex Cinnamomis, 20 parts of Styrax, 6 parts of Borneolum Syntheticums, 6 parts of Venenum Bufoniss, 10 parts of Eupolyphaga Seu Steleophagas and adjuvant, is prepared from.
2. described in preparation claim 1, treat the method for the pharmaceutical composition of coronary heart disease; it is characterized in that: proportionally take Moschus, Calculus Bovis, Radix Ginseng extract, Cortex Cinnamomi, Styrax, Borneolum Syntheticum, Venenum Bufonis and Eupolyphaga Seu Steleophaga; combine with acceptable pharmaceutic adjuvant in medicine; and process according to conventional preparation method, make corresponding pharmaceutical preparation.
3. method according to claim 2; it is characterized in that: the pharmaceutical composition of described treatment coronary heart disease is prepared by the following method: Moschus, Calculus Bovis, Radix Ginseng extract, Cortex Cinnamomi, Borneolum Syntheticum, Venenum Bufonis and Eupolyph aga sinesis Walker are broken into fine powder; mix with Styrax and conventional adjuvant, according to conventional method, make pharmaceutical preparation.
4. method according to claim 2, is characterized in that: the pharmaceutical composition of described treatment coronary heart disease is prepared by the following method: Calculus Bovis, Radix Ginseng extract are ground into respectively fine powder; Moschus is pulverized, and doubly measures alcohol reflux 1-3 time of 60-90% with 5-20, each 2-6 hour, and filtration, filtrate recycling ethanol, obtains Moschus extract; Venenum Bufonis is pulverized, and doubly measures alcohol reflux 1-3 time of 60%-95% with 30-100, each 0.5-3 hour, and filtration, filtrate recycling ethanol, obtains Venenum Bufonis extract; Eupolyphaga Seu Steleophaga is pulverized, and with 5-20, doubly measures water boiling and extraction 1-4 time, and each 0.5-3 hour, filters, concentrated, obtains Eupolyphaga seu steleophaga extract; Cortex Cinnamomi adds 8-10 times of water gaging, with hydrodistillation, extracts volatile oil, obtains Cortex Cinnamomi volatile oil; Styrax, Borneolum Syntheticum are used respectively dissolve with ethanol; Above-mentioned bovine calculus powder, Radix Ginseng extract powder, Moschus extract, Venenum Bufonis extract, Eupolyphaga seu steleophaga extract, Cortex Cinnamomi volatile oil, Styrax dissolve with ethanol liquid, Borneolum Syntheticum dissolve with ethanol liquid and conventional adjuvant are mixed, according to conventional method, make pharmaceutical preparation.
5. according to method described in any one in claim 2-4, it is characterized in that: described pharmaceutical preparation is selected from: tablet, capsule, oral liquid, syrup, drop pill, suck agent, granule, pill, powder, unguentum, sublimed preparation, suspensoid, solution, ejection preparation, suppository, cream, spray or patch.
6. method according to claim 5, is characterized in that: described pharmaceutical preparation is tablet, capsule, granule, pill or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110247040.2A CN102526195B (en) | 2011-08-24 | 2011-08-24 | Medicinal composition for treating coronary disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110247040.2A CN102526195B (en) | 2011-08-24 | 2011-08-24 | Medicinal composition for treating coronary disease and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102526195A CN102526195A (en) | 2012-07-04 |
| CN102526195B true CN102526195B (en) | 2014-03-26 |
Family
ID=46335016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110247040.2A Active CN102526195B (en) | 2011-08-24 | 2011-08-24 | Medicinal composition for treating coronary disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102526195B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435114B (en) * | 2014-03-28 | 2018-04-13 | 上海和黄药业有限公司 | A kind of preparation method of cardiovascular disease medicine particulate ball |
| CN107669738B (en) * | 2017-10-18 | 2020-10-16 | 广东大鹏医药科技有限公司 | Traditional Chinese medicine preparation for promoting blood circulation to remove blood stasis, tonifying qi and strengthening heart and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225203A (en) * | 1987-07-01 | 1993-07-06 | Kim Young S | Pharmaceutical liquid composition containing Bezoar bovis |
| CN1557426A (en) * | 2004-02-11 | 2004-12-29 | 冯学君 | Preparation of moschus for refreshment |
| CN1839940A (en) * | 2006-01-05 | 2006-10-04 | 高成富 | Musk formulation for protecting heart and its preparation method |
| CN101549014A (en) * | 2008-04-02 | 2009-10-07 | 北京卓越同创药物研究院 | Heart-protecting musk oral preparation and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090016525A (en) * | 2007-08-11 | 2009-02-16 | 김덕희 | Candy has medical stuff |
-
2011
- 2011-08-24 CN CN201110247040.2A patent/CN102526195B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225203A (en) * | 1987-07-01 | 1993-07-06 | Kim Young S | Pharmaceutical liquid composition containing Bezoar bovis |
| US5225203C1 (en) * | 1987-07-01 | 2001-05-15 | Kim Won Kyq Son | Pharmaceutical liquid composition containing bezoar bovis |
| CN1557426A (en) * | 2004-02-11 | 2004-12-29 | 冯学君 | Preparation of moschus for refreshment |
| CN1839940A (en) * | 2006-01-05 | 2006-10-04 | 高成富 | Musk formulation for protecting heart and its preparation method |
| CN101549014A (en) * | 2008-04-02 | 2009-10-07 | 北京卓越同创药物研究院 | Heart-protecting musk oral preparation and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102526195A (en) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT5433B (en) | Pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases | |
| WO2022036779A1 (en) | Huashibaidu granule, preparation method therefor and anti-viral drug | |
| CN103845418B (en) | A kind of Chinese medicine composition for the treatment of retinal hemorrhage and uses thereof | |
| CN102526065A (en) | Compound injection preparation for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN102526195B (en) | Medicinal composition for treating coronary disease and preparation method thereof | |
| CN112245552B (en) | Traditional Chinese medicine preparation with anti-atherosclerosis effect, preparation method and application | |
| CN102085257B (en) | Preparation method of micro-pills prepared from cassia twig and tuckahoe | |
| CN102309575B (en) | Application of medicinal composition in preparing medicament for treating diabetic complication | |
| CN101549014A (en) | Heart-protecting musk oral preparation and preparation method thereof | |
| WO2012079419A1 (en) | Pharmaceutical composition for treating macular degeneration | |
| CN107744571B (en) | Pharmaceutical composition for improving vascular endothelial dysfunction and preparation method and application thereof | |
| CN104083553B (en) | For preventing or treating the Chinese medicine extract of coronary heart disease, compositions and its production and use | |
| CN105267867A (en) | Application of traditional Chinese medicine to preparation of medicine for eliminating heart toxic and side effects of antitumor medicine or preparation of medicine with synergic antitumor effect with adriamycin | |
| CN102309632B (en) | Application of pharmaceutical composition in preparation of pharmaceuticals for treating complications of diabetes | |
| CN104324250A (en) | Traditional Chinese medicine composition for cerebral arterial thrombosis and preparation method of traditional Chinese medicine composition | |
| CN107982484A (en) | Treat Chinese medicinal compound extract of diabetic retinopathy and its preparation method and application | |
| CN103372138B (en) | A kind of pharmaceutical composition containing Shengmai Yin active ingredient and preparation method thereof | |
| CN114588236A (en) | Use of a composition for the manufacture of a medicament | |
| CN104689079A (en) | Traditional Chinese medicine composition for treating diabetic retinopathy and preparation method thereof | |
| CN101176751B (en) | Pharmaceutical composition of red sage root and cassia twig | |
| CN1718191A (en) | Total secondary ginseng glucoside oral disintegration tablets prepn. method and application thereof | |
| CN104491612A (en) | Purpose of traditional Chinese medicine composition in preparing medicament for treating diabetic retinopathy | |
| CN111643606B (en) | Gel plaster for treating insomnia and preparation method thereof | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN103690672B (en) | For treating controlled release preparation of anovulatory dysfunctional uterine hemorrhage that women's ovary dysfunction causes and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180601 Address after: No. 1, Beijing Road, Yunyan District, Guizhou Province, Guizhou Patentee after: Guizhou Shenqi Drug Research Institute Address before: No. 1 Beijing Road, Guiyang, Guizhou Patentee before: Guizhou Maojka Group Holding Co., Ltd. |
|
| TR01 | Transfer of patent right |